Managed Care - March 2009 - (Page 1) In moderate-risk* regimens Approach chemotherapy with confidence by reducing the risk of febrile neutropenia Neulasta® (pegfilgrastim) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia. Important Safety Information Splenic rupture (including fatal cases), acute respiratory distress syndrome, and sickle cell crises have been reported. Allergic reactions, including anaphylaxis, have also been reported. The majority of these reactions occurred upon initial exposure. However, in rare cases, allergic reactions, including anaphylaxis, recurred within days after discontinuing anti-allergic treatment. In a placebo-controlled trial, bone pain occurred at a higher incidence in Neulasta®-treated patients as compared to placebotreated patients (31% vs. 26%). The most common adverse events reported in either placebo- or active-controlled trials were consistent with the underlying cancer diagnosis and its treatment with chemotherapy, with the exception of bone pain. Please refer to brief summary of Neulasta® Prescribing Information. *Regimens associated with ≥ 17% risk of febrile neutropenia. © 2009 Amgen. All rights reserved. MC41456-C 12-08 Class I www.neulasta.com Consequences of febrile neutropenia, such as hospitalization, may impact patient care First- and subsequent-cycle Neulasta® achieved significant results in patients receiving a moderate-risk* regimen: I 94% reduction in febrile neutropenia vs. placebo (17% vs. 1%).1,2 I 93% reduction in febrile neutropenia–related hospitalization vs. placebo (14% vs. 1%).1,2 Neulasta® is given once per chemotherapy cycle and should not be administered in the period between 14 days before and 24 hours after administration of cytotoxic chemotherapy. Start with support http://www.neulasta.com http://www.neulasta.com
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.